You are free to share (copy and redistribute) this article in any medium or format within the ... using their persuasive written and oral presentations to complete a research proposal, final report, ...

The choice of an irrigating solution for use in infected root canals requires previous knowledge of the microorganisms responsible for the infectious process as well as the properties of different ...

*Note: One patient in each cohort finished treatment without at least one post-baseline tumor assessment. Among the patients with PD-L1 TPS<1%, IBI363 demonstrated outstanding efficacy signals: in ...

announced the third oral presentation of clinical data for IBI363 (first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein) in advanced non-small cell lung cancer at the 2025 American ...

announced the third oral presentation of clinical data for IBI363 (first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein) in advanced non-small cell lung cancer at the 2025 American ...

YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a ...

SAN FRANCISCO, and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

In terms of safety, among participants receiving monotherapy and combination therapy, 19 (27.9%) and 26 (35.6%) reported treatment-related adverse events (TRAEs) of Grade 3 or higher ...

today announced that it will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held June 5-7, 2025, in Montreal, Canada.